ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Belief Biomed's Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China
August 11, 2021On August 10th, 2021，Belief Biomed announced that China's National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief Biomed's BBM-H901. -
Freeline modifies clinical development plan for Hemophilia B programme
February 10, 2021Clinical-stage biotechnology company Freeline Therapeutics has announced a modification to the clinical development plan for its FLT180a programme for Hemophilia B. -
Novo Nordisk launches Rebinyn, a new, long-acting treatment for patients with hemophilia B in Canada
April 12, 2018Novo Nordisk announced the launch and availability of Rebinyn® (Coagulation Factor IX (Recombinant), pegylated) -
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
November 09, 2017Spark Therapeutics (NASDAQ: ONCE) and Pfizer (NYSE: PFE) have amended their license agreement for hemophilia B's investigational gene therapy, SPK-9001 -
UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal tr
October 20, 2017UniQure has modified its hemophilia B gene therapy to dial up factor IX (FIX) activity to the levels achieved by Spark Therapeutics’ rival product.
Pharma Sources Insight January 2025
